Status:
UNKNOWN
Cardiometabolic Syndrome Response to Therapeutic Lifestyle Changes
Lead Sponsor:
Holy Cross Hospital, Florida
Conditions:
Metabolic Syndrome
ASCVD
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Intensive lifestyle intervention has shown to be effective in high risk patient populations and has gathered support from leaders-as outlined in the 2015 consensus paper by the Cardiometabolic Health ...
Eligibility Criteria
Inclusion
- Metabolic syndrome patients meeting 3 of 5 criteria:
- waist circumference (37 in) in white and AA men, (35 in) in Asian men, and (31.5 in) in women;
- triglycerides ≥150 mg/dl;
- high-density lipoprotein cholesterol (HDL-C) \<40 mg/dl in men and \<50 mg/dl in women;
- blood pressure ≥130/85 mm Hg
- fasting glucose ≥100 mg/d or HgbA1c ≥ 5.71 (includes diabetics)
- Patients requiring secondary ASCD prevention
Exclusion
- Patients with less than 5 year survival
- Patients with cancer undergoing therapy or on palliative treatment
- Patients with end stage heart failure
Key Trial Info
Start Date :
October 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04093440
Start Date
October 1 2019
End Date
December 1 2021
Last Update
September 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Internal Medicine Residency Clinic at Holy Cross Hospital
Fort Lauderdale, Florida, United States, 33334